The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Tesa M Severson; Denise M Wolf; Christina Yau; Justine Peeters; Diederik Wehkam; Philip C Schouten; Suet-Feung Chin; Ian J Majewski; Magali Michaut; Astrid Bosma; Bernard Pereira; Tycho Bismeijer; Lodewyk Wessels; Carlos Caldas; Rene Bernards; Iris M Simon; Annuska M Glas; Sabine Linn; Laura van 'T Veer

Journal article

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Tesa M Severson, Denise M Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C Schouten, Suet-Feung Chin, Ian J Majewski, Magali Michaut, Astrid Bosma, Bernard Pereira, Tycho Bismeijer, Lodewyk Wessels, Carlos Caldas, Rene Bernards, Iris M Simon, Annuska M Glas, Sabine Linn, Laura van 'T Veer

Breast Cancer Research | BMC | Published : 2017

DOI: 10.1186/s13058-017-0861-2

University of Melbourne Researchers

Ian Majewski Author Medical Biology (W.E.H.I.)

Grants

Awarded by RATHER Consortium: the collaborative European Union - RATHER project (Rational Therapy for Breast Cancer)

Funding Acknowledgements

This study was supported by the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (Rational Therapy for Breast Cancer) (protect number: 258967) (www.ratherproject.com) and I-SPY 2 TRIAL investigators (ispy2.org).